Genta Takes Over Development Of Daiichi Sankyo's Tesetaxel
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
After the oral taxane was put on clinical hold, Genta says it has clear guidance from FDA on how to proceed with development
You may also be interested in...
Genta appeals "not approvable" decision for Genasense
In response to a December 2006 "not approvable" letter for Genasense, Genta appeals the decision through the agency's formal dispute resolution process. The firm seeks approval of the Bcl-2 inhibitor for use in combination with fludarabine and cyclophosphamide to treat patients with relapsed or refractory chronic lymphocytic leukemia. Among the firm's arguments in the appeal are that the pivotal Phase III trial achieved its primary endpoint of complete response, which was doubled in the treatment arm compared to the control group (17 percent vs. 7 percent), and that complete response confers clinical benefit in CLL. Responses to CDER appeals are typically made within 30 to 60 days...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.